TransMedics Group, Inc. (TMDX) Price History:-36.48%(TTM)
Over the latest trailing 12-month period, TransMedics Group, Inc. (TMDX)'s price cagr is -36.48%. The comparable SPY value is +25.01%. Year-to-date price return is -35.78%. Price CAGR uses adjusted close price history and excludes dividends.
Current Price
$78.79
+$5.57 (+7.61%)
Previous Close: $73.22
Last Session
- Open
- $75.26
- Day High
- $80.72
- Day Low
- $75.12
- Volume
- 1.79M
- Avg Volume
- 1.31M
52-Week Position
19%
of the 52-week price range
- From 52-week high
- -49.49%
- From 52-week low
- +31.09%
52-Week Price Range
52-Week Low
$60.11
May 14, 2026
Current Price
$78.79
19% of range
52-Week High
$156.00
Dec 1, 2025
Price Returns by Period
1 Day
+7.61%
7 Days
+8.06%
30 Days
+14.44%
YTD
-35.78%
1 Year
-36.23%
vs 52W High
-49.49%
TMDX Price Chart
Long-Term Performance (CAGR)
Price CAGR (3Y)
+0.07%
Price CAGR (5Y)
+21.48%
Total Return CAGR (3Y)
+0.07%
Total Return CAGR (5Y)
+21.48%
CAGR (Compound Annual Growth Rate) shows the annualized return over the specified period. Total Return includes dividends reinvested.
Key Price Statistics
| Current Price | $78.79 |
| Previous Close | $73.22 |
| Day Range | $75.12 - $80.72 |
| 52-Week Range | $60.11 - $156.00 |
| Volume | 1.79M |
| Average Volume | 1.31M |
| Market Cap | $2.72B |
| % from 52W High | -49.49% |
Related Metrics
About TransMedics Group, Inc.
TransMedics Group, Inc. operates as a commercial-stage medical technology enterprise, committed to transforming the landscape of organ transplant therapy for patients worldwide grappling with end-stage organ failure. At the core of their offerings is the Organ Care System (OCS), an innovative, portable solution engineered to perfuse, optimize, and continuously monitor donor organs. This system leverages exclusive, tailored technology to meticulously recreate near-physiological conditions for these vital organs while they remain outside the human body. The OCS suite encompasses specialized modules: OCS LUNG, which facilitates the preservation of standard criteria donor lungs for double-lung transplants; OCS Heart, designed for the extracorporeal perfusion and maintenance of donor hearts; and OCS Liver, dedicated to the preservation of donor livers. Founded in 1998, TransMedics is headquartered in Andover, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Waleed H. Hassanein